Published and unpublished studies by investigators in the pharmaceutical industry indicate that a disturbingly high number of academic laboratories’ reports nominating potential new cancer-drug targets are either non-reproducible or, if reproducible, are not sufficiently robust to form the basis for drug-discovery efforts.
Source: NIH
